Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study

Akarin Hiransuthikul, Rena Janamnuaysook, Kanittha Himmad, Stephen J Kerr, Narukjaporn Thammajaruk, Tippawan Pankam, Kannapat Phanjaroen, Stephen Mills, Ravipa Vannakit, Praphan Phanuphak, Nittaya Phanuphak, iFACT Study Team, Akarin Hiransuthikul, Rena Janamnuaysook, Kanittha Himmad, Stephen J Kerr, Narukjaporn Thammajaruk, Tippawan Pankam, Kannapat Phanjaroen, Stephen Mills, Ravipa Vannakit, Praphan Phanuphak, Nittaya Phanuphak, iFACT Study Team

Abstract

Introduction: Concerns over potential drug-drug interactions (DDI) between feminizing hormone therapy (FHT) and pre-exposure prophylaxis (PrEP) have hampered uptake and adherence of PrEP among transgender women (TGW). To determine DDI between FHT and PrEP, we measured the pharmacokinetic (PK) parameters of blood plasma estradiol (E2) and tenofovir (TFV) in Thai TGW.

Methods: Twenty TGW who never underwent orchiectomy and had not received injectable FHT within six months were enrolled between January and March 2018. FHT (E2 valerate and cyproterone acetate) were prescribed to participants at baseline until week 5, and then from week 8 until the end of study. Daily PrEP (tenofovir disoproxil fumarate/emtricitabine) was initiated at week 3 and continued without interruption. Intensive E2 PK parameters and testosterone concentration at 24 hours (C24 ) were measured at weeks 3 (without PrEP) and 5 (with PrEP), and intensive TFV PK parameters were measured at weeks 5 (with FHT) and 8 (without FHT).

Results: Median (interquartile range) age, body mass index, and creatinine clearance were 21.5 (21-26) years, 20.6 (19.0-22.4) kg/m2 , and 116 (101-126.5) mL/min, respectively. The geometric mean (%CV) of area under curve from time zero to 24 hours (AUC0-24 ), maximum concentration (Cmax ), and C24 of E2 at weeks 3 and 5 were 775.13 (26.2) pg h/mL, 51.47 (26.9) pg/mL, and 15.15 (42.0) pg/mL; and 782.84 (39.6), 55.76 (32.9), and 14.32 (67.4), respectively. The geometric mean (%CV) of TFV AUC0-24 , Cmax , and C24 at weeks 5 and 8 were 2242.1 (26.5) ng h/mL, 353.9 (34.0) ng/mL, and 40.9 (31.4) ng/mL; and 2530.2 (31.3), 311.4 (30.0), and 49.8 (29.6), respectively. The geometric mean of TFV AUC0-24 and C24 at week 5 were significantly less than that at week 8 by 12% (p = 0.03) and 18% (p < 0.001), respectively. There were no significant changes in E2 PK parameters and median C24 of bioavailable testosterone between week 3 and week 5.

Conclusions: Our study demonstrated lower blood plasma TFV exposure in the presence of FHT, suggesting that FHT may potentially affect PrEP efficacy among TGW; but E2 exposure was not affected by PrEP. Further studies are warranted to determine whether these reductions in TFV are clinically significant. Clinical Trial Number: NCT03620734.

Keywords: drug-drug interactions; feminizing hormone; pre-exposure prophylaxis; prevention; transgender women.

© 2019 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Figures

Figure 1. iFACT study scheme
Figure 1. iFACT study scheme
FHT was initiated at week 0 until week 5, and later restarted at week 8 until the completion of study period. PrEP containing TFV disoproxil fumarate and emtricitabine was initiated at week 3 and continued without interruption until the completion of study period. Intensive PK parameters of E2 were assessed at week 3 (FHT only) and week 5 (PrEP and FHT). Intensive PK parameters of TFV were assessed at week 5 (PrEP and FHT) and week 8 (PrEP only). Testosterone concentration at 24 hours (C24) was also measured at week 3 and week 5 to indirectly determine the anti‐androgen effect of FHT. C24, concentration at 24 hours; E2, estradiol; FHT, feminizing hormone therapy; iFACT, Interaction between the use of FHT and Antiretroviral agents Concomitantly among TGW; PK, pharmacokinetics; PrEP, pre‐exposure prophylaxis; TFV, tenofovir.
Figure 2. Median estradiol (E2) concentration‐times curves…
Figure 2. Median estradiol (E2) concentration‐times curves at week 3 and week 5
Error bars represent the 25th to 75th percentile. Week 5 times have been offset by 0.4 hours to improve readability.
Figure 3. Median tenofovir (TFV) concentration‐times curves…
Figure 3. Median tenofovir (TFV) concentration‐times curves at week 5 and week 8
Error bars represent the 25th to 75th percentile. Week 8 times have been offset by 0.4 hours to improve readability.

References

    1. Baral SD, Poteat T, Stromdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta‐analysis. Lancet Infect Dis. 2013;13(3):214–22.
    1. Guadamuz TE, Wimonsate W, Varangrat A, Phanuphak P, Jommaroeng R, McNicholl JM, et al. HIV prevalence, risk behavior, hormone use and surgical history among transgender persons in Thailand. AIDS Behav. 2011;15(3):650–8.
    1. van Griensven F, Na Ayutthaya PP, Wilson E. HIV surveillance and prevention in transgender women. Lancet Infect Dis. 2013;13(3):185–6.
    1. Seekaew P, Pengnonyang S, Jantarapakde J, Sungsing T, Rodbumrung P, Trachunthong D, et al. Characteristics and HIV epidemiologic profiles of men who have sex with men and transgender women in key population‐led test and treat cohorts in Thailand. PLoS ONE. 2018;13(8):e0203294.
    1. Coleman E, Bockting W, Botzer M, Brown G, Cohen‐Kettenis P, DeCuypere G, et al. Standards of care (soc) for the health of transsexual, transgender, and gender nonconforming people. Georgia: World Professional Association Transgender Health; 2011.
    1. Radix A, Sevelius J, Deutsch MB. Transgender women, hormonal therapy and HIV treatment: a comprehensive review of the literature and recommendations for best practices. J Int AIDS Soc. 2016;19 3 Suppl 2:20810.
    1. Chokrungvaranont P, Selvaggi G, Jindarak S, Angspatt A, Pungrasmi P, Suwajo P, et al. The development of sex reassignment surgery in Thailand: a social perspective. Sci World J. 2014;2014:5.
    1. Gooren LJ, Sungkaew T, Giltay EJ. Exploration of functional health, mental well‐being and cross‐sex hormone use in a sample of Thai male‐to‐female transgendered persons (kathoeys). Asian J Androl. 2013;15(2):280–5.
    1. Nemoto T, Iwamoto M, Perngparn U, Areesantichai C, Kamitani E, Sakata M. HIV‐related risk behaviors among kathoey (male‐to‐female transgender) sex workers in Bangkok, Thailand. AIDS Care. 2012;24(2):210–9.
    1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.
    1. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.
    1. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double‐blind, placebo‐controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.
    1. Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, et al. HIV pre‐exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV. 2015;2(12):e512–9.
    1. Yang D, Chariyalertsak C, Wongthanee A, Kawichai S, Yotruean K, Saokhieo P, et al. Acceptability of pre‐exposure prophylaxis among men who have sex with men and transgender women in northern Thailand. PLoS ONE. 2013;8(10):e76650.
    1. Sevelius JM, Patouhas E, Keatley JG, Johnson MO. Barriers and facilitators to engagement and retention in care among transgender women living with human immunodeficiency virus. Ann Behav Med. 2014;47(1):5–16.
    1. Sevelius JM, Keatley J, Calma N, Arnold E. “I am not a man”: trans‐specific barriers and facilitators to PrEP acceptability among transgender women. Glob Public Health. 2016;11(7–8):1060–75.
    1. Poteat T, Wirtz AL, Radix A, Borquez A, Silva‐Santisteban A, Deutsch MB, et al. HIV risk and preventive interventions in transgender women sex workers. Lancet. 2015;385(9964):274–86.
    1. University of California, San Francisco . (2011) Review of literature relating to possible drug interactions between antiretrovirals and estrogen therapy used for MTF gender transition. [cited 2018 Sep 8]. Available from:
    1. Rubinow KB. Estrogens and Body Weight Regulation in Men. Adv Exp Med Biol. 2017;1043:285–313.
    1. Jankowska EW, Medras M, Rogucka EA. Body mass index, waist/hip ratio and androgen‐estrogen activity in younger versus older Polish men. Aging Male. 2000;3(4):177–84.
    1. Center of Excellence for Transgender Health, Department of Family and Community Medicine, University of California San Francisco . Guidelines for the primary and gender‐affirming care of transgender and gender nonbinary people. 2nd ed In: Deutsch MB, editor. 2016. Jun [cited 2018 Sep 8]. Available from:
    1. Wilczynski C, Emanuele MA. Treating a transgender patient: overview of the guidelines. Postgrad Med. 2014;126(7):121–8.
    1. Health Policy Project, A.P.T.N., United Nations Development Programme . Blueprint for the provision of comprehensive care for trans people and trans communities. Washington (DC): Futures Group, Health Policy Project; 2015.
    1. Droste JAH, Verweij‐van Wissen CPWGM, Kearney BP, Buffels R, vanHorssen PJ, Hekster YA, et al. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers. Antimicrob Agents Chemother. 2005;49(2):680.
    1. Soares F, Douurado I, Magno L, Vasconcelos d, Nunn A, PopTrans Study Group . Transgender women willingness to use PREP in northeastern Brazil. 9th IAS Conference on HIV Science (IAS 2017); 2017 Jul 23‐26; Paris, France.
    1. Restar AJ, Kuhns L, Reisner S, Garofalo R, Mimiaga ML. Acceptability of PrEP among a large cohort of young transgender women in 2 US cities. Conference on Retroviruses and Opportunistic Infections (CROI2018); 2018 Mar 4‐7; Boston, MA.
    1. Poteat T, Cooney E, Malik M, Yamanis T, Lujan M, Wirtz AL. Predictors of willingness to take PREP among black and Latina transgender women. Conference on Retroviruses and Opportunistic Infections (CROI2018); 2018 Mar 4‐7; Boston, MA.
    1. Cottrell ML, Prince HM, Maffuid K, Poliseno A, White N, Sykes C, et al. Altered TDF/FTC pharmacology in a transgender female cohort: Implications for PrEP. 22nd International AIDS Conference (AIDS2018); 2018 Jul 23‐27; Paris, France.
    1. Shieh E, Marzinke M, Fuchs E, Bakshi R, Wutyi A, Poteat T, et al. Transgender women on estrogen have significantly lower tenofovir/emtricitabine concentrations during directly observed dosing when compared to cis men. HIVR4P; 2018 Oct 21‐25; Madrid, Spain.
    1. Todd CS, Deese J, Wang M, Hubacher D, Steiner MJ, Otunga S, et al. Sino‐implant (II)(R) continuation and effect of concomitant tenofovir disoproxil fumarate‐emtricitabine use on plasma levonorgestrel concentrations among women in Bondo, Kenya. Contraception. 2015;91(3):248–52.
    1. Kearney BP, Mathias A. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives. Pharmacotherapy. 2009;29(8):924–9.
    1. Murnane PM, Heffron R, Ronald A, Bukusi EA, Donnell D, Mugo NR, et al. Pre‐exposure prophylaxis for HIV‐1 prevention does not diminish the pregnancy prevention effectiveness of hormonal contraception. AIDS. 2014;28(12):1825–30.
    1. Callahan R, Nanda K, Kapiga S, Malahleha M, Mandala J, Ogada T, et al. Pregnancy and contraceptive use among women participating in the FEM‐PrEP trial. J Acquir Immune Defic Syndr. 2015;68(2):196–203.
    1. Heffron R, Mugo N, Were E, Kiarie J, Bukusi EA, Mujugira A, et al. Preexposure prophylaxis is efficacious for HIV‐1 prevention among women using depot medroxyprogesterone acetate for contraception. AIDS. 2014;28(18):2771–6.
    1. Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66(3):340–8.
    1. Janamnuaysook R, Samitpol K, Ketwongsa P, Chancham A, Kongkapan J, Mingkwanrungruang P, et al. Integrated gender affirmative hormone treatment services improve access to and retention in HIV testing, syphilis testing and pre‐exposure prophylaxis (PrEP) service uptake among transgender women in Thailand. 22nd International AIDS Conference (AIDS2018); 2018 Jul 23‐27; Paris, France.
    1. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.
    1. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir‐based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.
    1. Davies O, Alexander H, Robinson N, Pace M, Brady M, Frater J, et al. Failure of daily tenofovir to prevent HIV transmission or the establishment of a significant viral reservoir despite continued antiretroviral therapy. J Int AIDS Soc. 2014;17 4 Suppl 3:19731.
    1. Jeffcoate WJ, Matthews RW, Edwards CR, Field LH, Besser GM. The effect of cyproterone acetate on serum testosterone, LH, FSH, and prolactin in male sexual offenders. Clin Endocrinol. 1980;13(2):189–95.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa